Evidence map›Paper›PMID 41797328›Full record

ArticlePharmaceutical statistics

"Within-Trial" Prognostic Score Adjustment Is Targeted Maximum Likelihood Estimation.

Emilie Højbjerre-Frandsen, Alejandro Schuler

Abstract read
In one paragraph

Article in Pharmaceutical statistics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emilie Højbjerre-FrandsenBiostatistics Methods, Novo Nordisk A/S, Søborg, Denmark.ORCID 0009-0008-0996-4363
Alejandro SchulerDivision of Biostatistics, University of California Berkeley, Berkeley, California, USA.

Funding

Innovationsfonden 2052-00044B
6 · The paper itself

Abstract

Adjustment for "super" or "prognostic" composite covariates has become more popular in randomized trials recently. These prognostic covariates are often constructed from historical data obtained from previous clinical trials or registries by fitting a predictive model of the outcome on the raw covariates. A natural question that we have been asked by applied researchers is whether this can be done without the historical data: can the prognostic covariate be constructed or derived from the trial data itself, possibly using different folds of the data, before adjusting for it? Here we clarify that such "within-trial" prognostic adjustment is nothing more than a form of targeted maximum likelihood estimation (TMLE), a well-studied procedure that typically improves the power of trial analyses. We therefore argue that there is no reason to reinvent the wheel: within-trial prognostic score adjustment should be referred to as TMLE, without qualification.

Indexed as

Randomized Controlled Trials as TopicResearch DesignHumansLikelihood FunctionsModels, StatisticalPrognosiscausal inferenceprognostic scoresrandomized trialstargeted learning

Identifiers

PMID41797328
PMCPMC12968522

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.